Who makes Dasatinib as dispersed tablets?

Dasatinib as dispersed tablets is developed by Bristol-Myers Squibb.

What development phase is Dasatinib as dispersed tablets in?

Dasatinib as dispersed tablets is in Phase 1.

Last reviewed 2026-05-14 · How we verify

Dasatinib as dispersed tablets

Bristol-Myers Squibb · Phase 1 active Small molecule

At a glance

Generic name	Dasatinib as dispersed tablets
Also known as	Dasatinib/BMS-354825
Sponsor	Bristol-Myers Squibb
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dasatinib as dispersed tablets CI brief — competitive landscape report
Dasatinib as dispersed tablets updates RSS · CI watch RSS
Bristol-Myers Squibb portfolio CI